A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer
| العنوان: | A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer |
|---|---|
| المؤلفون: | Youxin Ji, Zhen Zhang, Chunling Zhang, Keke Nie, Xingjun Zhuang, Yunhong You |
| المصدر: | Thoracic Cancer, Vol 11, Iss 1, Pp 8-14 (2020) Thoracic Cancer |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Lung Neoplasms, Bevacizumab, Pleural effusion, Equivalence Trials as Topic, Gastroenterology, lcsh:RC254-282, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Malignant pleural effusion, Humans, In patient, Infusions, Parenteral, malignant pleural effusion, Lung cancer, Infusions, Intravenous, non‐small‐cell lung cancer, Proteinuria, vascular endothelial growth factor, business.industry, General Medicine, Original Articles, Middle Aged, medicine.disease, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Pleural Effusion, Malignant, Vascular endothelial growth factor, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Toxicity, Female, Original Article, medicine.symptom, business, medicine.drug, Follow-Up Studies |
| الوصف: | Background To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). Methods Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two groups in 1:1 ratio. The pleural effusion was completely drained in 24 hours; one group received intrapleural infusion and the second group received intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight. The serum vascular endothelial growth factor (VEGF) was tested before and 72 hours after injection of bevacizumab. Computerized tomography (CT) scan to evaluate pleural effusions was carried out at four weeks for each patient and their survival followed-up. Results A total of 67 patients were screened and 43 enrolled into the study. The response rate was 80% (16 of 20) in the intrapleural group and 66.7% (14 of 21) in the intravenous group. The median duration of response (DoR) of pleural effusion was 4.50 months and 3.70 months, respectively. The median serum VEGF level at 72 hours decreased 67.25% in the intrapleural group and 57.19% in the intravenous group compared to baseline level (P = 0.276). The median serum VEGF level at 72 hours decreased 52.02% compared to baseline level in patients' DoR less than three months and 68.33% in patients' DoR longer than three months, respectively (P = 0.014). The main side effects noted were mild to moderate hypertension, proteinuria and epistaxis. Conclusions Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72 hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion. |
| اللغة: | English |
| تدمد: | 1759-7706 1759-7714 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f81f91ecd87d7bb2d0ed19156a451cd3 https://doaj.org/article/ed663cb83c404ad98d36a256eeb53ead |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....f81f91ecd87d7bb2d0ed19156a451cd3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597706 17597714 |
|---|